← Back to Search

Anti-metabolites

Tas-102 for Colorectal Cancer

Phase 1
Waitlist Available
Led By Nicholas Fidelman, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 years
Awards & highlights

Study Summary

This study is evaluating whether a combination of a drug and a radiation therapy is safe for people with cancer.

Eligible Conditions
  • Colorectal Cancer
  • Colon Cancer
  • Liver Metastases

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Determine dose limiting toxicities (DLT)
Maximum tolerated dose (MTD)
Secondary outcome measures
Biomarker response
Extrahepatic progression free survival (EHPFS)
Hepatic progression-free survival (HPFS)
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Tas-102 and radioembolizationExperimental Treatment2 Interventions
Combination therapy with Tas-102 and radioembolization using 90Y resin microspheres
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SIR-Sphere
2017
Completed Phase 3
~520
Tipiracil
FDA approved

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,505 Previous Clinical Trials
15,237,534 Total Patients Enrolled
Sirtex MedicalIndustry Sponsor
28 Previous Clinical Trials
4,249 Total Patients Enrolled
Taiho Pharmaceutical Co., Ltd.Industry Sponsor
63 Previous Clinical Trials
16,277 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases
2017. "Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02602327.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top